References
- Diabetes Foreningen. Facts about diabetes in Denmark – Diabetes [Internet]; [cited 2020 Nov 4]. Available from: https://diabetes.dk/diabetesforeningen/in-english/facts-about-diabetes-in-denmark.aspx.
- Carstensen B, Rønn PF, Jørgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in. BMJ Open Diab Res Care. 2020;8(1):e001071. http://drc.bmj.com/.
- Sortsø C, Green A, Jensen PB, et al. Societal costs of diabetes mellitus in Denmark. Diabet Med. 2016;33(7):877–885.
- Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. https://pubmed.ncbi.nlm.nih.gov/20594588/.
- Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. https://pubmed.ncbi.nlm.nih.gov/18539916/.
- Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853. http://www.thelancet.com/article/S0140673698070196/fulltext.
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. www.nejm.org.
- Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38. https://pubmed.ncbi.nlm.nih.gov/16824829/.
- Svensson E, Baggesen LM, Johnsen SP, et al. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators. Dia Care. 2017;40(6):800–807. http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-2271/-/DC1.
- Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes:impactofearlyglycemic control on future complications (the Diabetes & Aging study). Dia Care. 2019;42(3):416–426. http://care.diabetesjournals.org/lookup/suppl/http://www.diabetesjournals.org/content/diabetes-core-update-podcasts.
- Järvinen S, Laine MK, Eriksson JG. Comparison of use of diabetic medication and clinical guidelines in four Nordic countries. Ann Med. 2016;48(3):162–168. http://www.tandfonline.com/doi/full/10.3109/07853890.2016.1146825.
- Jensen ML, Jørgensen ME, Hansen EH, et al. Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: the importance of initiation. PLoS One. 2017;12(6):e0179546.
- Paul SK, Klein K, Maggs D, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):10.
- Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:178.
- Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12. https://pubmed.ncbi.nlm.nih.gov/27727005/.
- Reach G, Pechtner V, Gentilella R, et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–511. http://dx.doi.org/10.1016/j.diabet.2017.06.003.
- Palmer AJ, Clarke P, Gray A, et al. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting. Value Health. 2013;16(4):670–685. http://dx.doi.org/10.1016/j.jval.2013.01.002.
- Willis M, Fridhammar A, Gundgaard J, et al. Comparing the cohort and micro-simulation modeling approaches in cost-effectiveness modeling of type 2 diabetes mellitus: a case study of the IHE diabetes cohort model and the economics and health outcomes model of T2DM. Pharmacoeconomics. 2020;38(9):953–969.
- Metodevurderinger for legemidler – status og rapporter – Legemiddelverket [Internet]; [cited 2020 Nov 24]. Available from: https://legemiddelverket.no/offentlig-finansiering/metodevurderinger/.
- Tandvårds-Läkemedelförmånsverket – Tandvårds- och läkemedelsförmånsverket TLV [Internet]; [cited 2020. Nov 24]. Available from: https://www.tlv.se/.
- Lundqvist A, Steen Carlsson K, Johansen P, et al. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One. 2014;9(10):e110235. https://dx.plos.org/10.1371/journal.pone.0110235.
- Statens legmiddelverk. Hurtig metodevurdering ved forhåndsgodkjent refusjon § 2 – Ozempic (semaglutid) til behandling av type 2 diabetes mellitus. 2019.
- The Swedish Institute for Health Economics. IHE-DCM - IHE [Internet]; [cited 2021. Mar 10]. Available from: https://ihe.se/en/our-expertise/economic-modelling-in-diabetes-and-obesity/economic-modelling-of-diabetes/cohort-model-ihe-dcm/.
- Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: I. Model construction and assumptions. Diabetes Care. 1997;20(5):725–734. https://care.diabetesjournals.org/content/20/5/725.
- Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia. 2001;44(12):2140–2155. https://pubmed.ncbi.nlm.nih.gov/11793015/.
- Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year united kingdom prospective diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–1933. https://pubmed.ncbi.nlm.nih.gov/23793713/.
- Knudsen JS, Hulman A, Rønn PF, et al. Trends in HbA1c and LDL cholesterol in patients with type 2 diabetes receiving first-time treatment in Northern Denmark, 2000–2017: population-based sequential cross-sectional analysis. Diabetes Care. 2020;43(2):e17–E19.
- Endokrinologisk Selskab og Dansk Selskab for Almen Medicin. Farmakologisk behandling af type 2-diabetes 2018 Revision. 2018.
- Dansk Endokrinologisk Selskab. Behandling og kontrol af Type 2 Diabetes – Dansk Endokrinologisk Selskab [Internet]. 2019; [cited 2021 Mar 17]. Available from: https://endocrinology.dk/nbv/diabetes-melitus/behandling-og-kontrol-af-type-2-diabetes/.
- Chehregosha H, Khamseh ME, Malek M, et al. A view beyond HbA1c: role of continuous glucose monitoring. Diabetes Ther. 2019;10(3):853–863.
- Willis M, Asseburg C, Nilsson A, et al. Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: informing economic modeling. Value Health. 2017;20(3):357–371. http://dx.doi.org/10.1016/j.jval.2016.10.004.
- Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25(3):476–481.
- Kjellberg J, Tikkanen CK, Bagger M. Short-term societal economic burden of first-incident type 2 diabetes-related complications – a nationwide cohort study. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):577–586. https://pubmed.ncbi.nlm.nih.gov/33054434/.
- Carlsson KS, Lundqvist A. Påverkbara Kostnader För Typ 2-Diabetes År 2020 Och År 2030 I Sverige [Internet]. 2015 [cited 2020 Nov 11]. Available from: https://ihe.se/wp-content/uploads/2017/10/IHE-Rapport_2015_1.pdf.
- Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int. 2013;2013:1–8.
- Danmarks Statistik. INDKP104: Indkomster for personer over 14 år efter landsdel, enhed, køn, socioøkonomisk status og indkomsttype [Internet]; [cited 2021 Mar 17]. Available from: https://statistikbanken.dk/statbank5a/default.asp?w=1920.
- Thomsen RW, Baggesen LM, Svensson E, et al. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study. Diabetes Obes Metab. 2015;17(8):771–780. https://pubmed.ncbi.nlm.nih.gov/25929277/.
- Selected Chronic Diseases and severe mental disorders (RUKS) [Internet]; [cited 2020. Nov 4]. Available from: https://www.danishhealthdata.com/find-health-data/Udvalgte-kroniske-sygdomme-og-Svaere-Psykiske-Lidelser.
- Bain SC, Bekker Hansen B, Hunt B, et al. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2020;23(1):98–105. https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1645018.
- De Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol. 2014;80(1):47–56.
- Baxter M, Hudson R, Mahon J, et al. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med. 2016;33(11):1575–1581. https://pubmed.ncbi.nlm.nih.gov/26773733/.
- Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. https://www.nejm.org/doi/full/10.1056/nejmoa1800256.
- Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial . Diabetologia. 2016;59(11):2298–2307. http://link.springer.com/10.1007/s00125-016-4065-6.
- Gæde J, Oellgaard J, Ibsen R, et al. A cost analysis of intensified vs. conventional multifactorial therapy of patients with type 2 diabetes—The Steno 2 study. Diabetes. 2018;67(Supplement 1):162-OR. https://diabetes.diabetesjournals.org/content/67/Supplement_1/162-OR.
- Nordic Medico Statistical Committee. Financing of Health Care in the Nordic Countries. 2013.
- Persson F, Bodegard J, Lahtela JT, et al. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): a multinational observational study. Endocrinol Diabetes Metab. 2018;1(4):e00036.
- Knudsen JS, Baggesen LM, Lajer M, et al. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study. Shimosawa T, editor. PLoS One. 2020;15(3):e0229621. https://dx.plos.org/10.1371/journal.pone.0229621.